Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting

Reuters

May 23, 2025

Abbisko <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting

Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537975125"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537975125\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537975125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537975125","market":"us","top_or_hot":-1,"title":"Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Abbisko <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-23 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Abbisko <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL2bqVBy:1","article_id":"2537975125","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537975125","pubTimestamp":1747958664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology  Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor . The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","02256":"和誉-B"},"translate_title":"Abbisko Therapeutics将在2025年ASCO年会上展示匹米替尼3期研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":0.9},"content_text":"Abbisko Therapeutics to Present Phase 3 Study Results on Pimicotinib at 2025 ASCO Annual Meeting\n    \n\n        Abbisko Therapeutics, a subsidiary of Abbisko Cayman Ltd., has announced its participation in the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company is set to present the phase 3 study results of its self-developed small molecule CSF-1R inhibitor, pimicotinib, for the treatment of Tenosynovial Giant Cell Tumor (TGCT). The presentation will cover the efficacy, safety, and clinical outcomes of the study. Founded in April 2016 and based in Shanghai, Abbisko Therapeutics focuses on oncology and is committed to developing innovative medicines to address unmet medical needs both in China and globally. The ASCO Annual Meeting will be held in Chicago, USA, from May 30 to June 3, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}